Rare condition

Polyneuropathy associated with IgM monoclonal gammopathy

0

studies recruiting now

as of 7 Sept 2026

2

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

2 studies are registered for Polyneuropathy associated with IgM monoclonal gammopathy, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Keep watching

Get an email when a new Polyneuropathy associated with IgM monoclonal gammopathy study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Polyneuropathy associated with IgM monoclonal gammopathy

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Treatments being studied

6 approved treatments and 4 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Eplontersen Sodium (Wainua)Approved: Inotersen Sodium (Tegsedi)Approved: Patisiran Sodium (Onpattro)Approved: VutrisiranApproved: Vutrisiran Sodium (Amvuttra)Approved: Tafamidis Meglumine (Vyndaqel)
Phase 3Rituximab (Blitzima)
Phase 2/3Ranirestat
Phase 2/3Phenytoin (Dilabid)
Phase 2Levetiracetam (Desitrend)

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).